These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28974543)

  • 1. Spleen-derived IFN-γ induces generation of PD-L1
    Langereis JD; Pickkers P; de Kleijn S; Gerretsen J; de Jonge MI; Kox M
    J Leukoc Biol; 2017 Dec; 102(6):1401-1409. PubMed ID: 28974543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
    Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
    J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1.
    de Kleijn S; Langereis JD; Leentjens J; Kox M; Netea MG; Koenderman L; Ferwerda G; Pickkers P; Hermans PW
    PLoS One; 2013; 8(8):e72249. PubMed ID: 24015224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.
    Li W; Tu J; Liu X; Yang W
    Clin Exp Immunol; 2017 Oct; 190(1):8-18. PubMed ID: 28556912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune regulation of canine tumour and macrophage PD-L1 expression.
    Hartley G; Faulhaber E; Caldwell A; Coy J; Kurihara J; Guth A; Regan D; Dow S
    Vet Comp Oncol; 2017 Jun; 15(2):534-549. PubMed ID: 26842912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
    Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
    Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphonuclear Myeloid-Derived Cells That Contribute to the Immune Paralysis Are Generated in the Early Phase of Sepsis via PD-1/PD-L1 Pathway.
    Ao X; Yang Y; Okiji T; Azuma M; Nagai S
    Infect Immun; 2021 May; 89(6):. PubMed ID: 33753411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
    Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
    Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous programmed death ligand-1 restrains the development and onset of Sjӧgren's syndrome in non-obese diabetic mice.
    Zhou J; Jin JO; Kawai T; Yu Q
    Sci Rep; 2016 Dec; 6():39105. PubMed ID: 27966604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.
    Schachtele SJ; Hu S; Sheng WS; Mutnal MB; Lokensgard JR
    Glia; 2014 Oct; 62(10):1582-94. PubMed ID: 24890099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
    Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
    Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophils Which Migrate to Lymph Nodes Modulate CD4
    Castell SD; Harman MF; Morón G; Maletto BA; Pistoresi-Palencia MC
    Front Immunol; 2019; 10():105. PubMed ID: 30761151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
    Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.
    Yee D; Shah KM; Coles MC; Sharp TV; Lagos D
    J Biol Chem; 2017 Dec; 292(50):20683-20693. PubMed ID: 29066622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
    Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
    Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
    Yang J; Chen J; Liang H; Yu Y
    Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1/B7-H1 Inhibits Viral Clearance by Macrophages in HSV-1-Infected Corneas.
    Jeon S; Rowe AM; Carroll KL; Harvey SAK; Hendricks RL
    J Immunol; 2018 Jun; 200(11):3711-3719. PubMed ID: 29669784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.